BioEclipse is a company headquartered in the United States.
BioEclipse Therapeutics develops allogeneic and autologous immunotherapies designed to treat resistant and recurrent solid tumors by programming immune cells to attack cancer while stimulating the patient’s immune system.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.